The Wei Lab at the Institute for Systems Biology (ISB) is seeking highly-motivated postdoctoral candidates in the areas of cancer biology and translational cancer research.
The Wei Lab works in the highly cross-disciplinary field of molecular and cellular analysis, tumor epigenetics, and systems biomedicine. We develop and implement innovative single-cell multi-omics technologies with computational approaches to investigate the cutting-edge cancer biology questions with a balance between discovery and clinical translation. We are particularly interested in (1) tumor epigenetic plasticity/dysregulation and its contribution to the treatment-induced adaptive therapy resistance; (2) the cause and consequence of tumor heterogeneity for advancing cancer treatment; (3) liquid biopsy-based rare cell analysis for cancer diagnostics and immunotherapy. Please visit http://wei.systemsbiology.org for more information about the lab.
Candidates should have a Ph.D. in Biology, Biological or biomedical Engineering, Chemistry, or other related areas. They should have demonstrated the ability or potential to conduct interdisciplinary research with good communication skills and a strong publication record. Candidates with research experiences in tumor animal models, tumor epigenetics, tumor immunology, and/or bioinformatics are strongly preferred.
Interested applicants should submit their curriculum vitae and 1-page description of research.
ISB is an equal opportunity employer (M/F/minority/veteran/disabled status).
About the Institute for Systems Biology (ISB)
ISB is a collaborative and cross-disciplinary non-profit biomedical research institute based in Seattle WA, and focuses on some of the most pressing issues in human health, including brain health, cancer, sepsis ,and aging, as well as many chronic and infectious diseases. ISB currently hosts 12 research groups with expertise ranging across genetics, microbial genetics, complex molecular machines, macromolecular complexes, gene regulatory networks, immunology, molecular and cell biology, cancer biology, genomics, proteomics, protein chemistry, computational biology, and biotechnology. Unlike traditional academic departments, our faculty are cross-disciplinary, which enables us to take on big, complex problems.
ISB was created by genomics pioneer Dr. Leroy Hood in 2000 as the first-of-its-kind institute dedicated to systems biology. ISB is in the top ranks of scientific institutions worldwide. In 2012, the SCImago ranked ISB 4th worldwide on its Excellence Rate scale. ISB strives for a culture of academic excellence and champions sound scientific research that has real-world translational impact. ISB faculty members have launched several successful companies, including: Cytopeia (acquired by BD in 2008), Integrated Diagnostics, Macrogenics, NanoString Technologies, PACT Pharma, Isoplexis, Sofie Biosciences, and Accelerator Corporation. ISB is now an affiliate of Providence St. Joseph Health, one of the largest not-for-profit health care systems in the United States